Excision-repair cross-complementing 1 predicts response to cisplatin-based neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma

KOJI TANAKA1,2, YASUHIKO MOHRI1, MASAKI OHI1, TAKEHITO YOKOE1, YUHIKI KOIKE1, YUHIKI MORIMOTO1, CHIKAI MIKI1, HITOSHI TONOUCHI2 and MASATO KUSUNOKI1,2

Departments of 1Gastrointestinal and Pediatric Surgery, and 2Innovative Surgery, Division of Reparative Medicine, Institute of Life Sciences, Mie University Graduate School of Medicine, Mie 514-8507, Japan

Received November 11, 2008; Accepted May 8, 2009

DOI: 10.3892/mmr_00000190

Abstract. Low excision repair cross-complementing 1 (ERCC1) has been associated with a favorable response to cisplatin (CDDP) in several types of malignancies. The present study aimed to investigate whether ERCC1 predicts the response to CDDP-based chemoradiotherapy (CRT) in patients with esophageal squamous cell carcinoma (ESCC) and to evaluate the association between ERCC1 and platinum drug sensitivity in ESCC cell lines. ERCC1 mRNA levels in pre- and post-treatment tumoral and normal biopsies of 16 ESCC patients receiving CDDP-based CRT and in 4 ESCC cell lines were examined using real-time reverse transcription polymerase chain reaction. Pre-treatment tumoral ERCC1 was compared with clinicopathological variables and response to CRT. Responses to CDDP and oxaliplatin (OXA) in ESCC cell lines were evaluated using the WST-8 colorimetric assay by comparing ERCC1 levels. ERCC1 was significantly higher in cancer tissue compared to normal tissue (p<0.01). Tumoral ERCC1 significantly decreased after CRT to normal levels (p<0.05). ERCC1 levels in patients with a partial response were significantly lower than levels in patients who did not respond to CRT (p<0.05). ESCC cell lines with lower ERCC1 showed significantly greater sensitivity to clinically relevant concentrations of CDDP and OXA compared to lines with higher ERCC1 (p<0.01). In conclusion, low ERCC1 levels were associated with platinum drug sensitivity in ESCC cell lines. Pre-treatment tumoral ERCC1 may be used as a predictive marker for identifying patients who respond to CRT.

Introduction

Prognosis in advanced esophageal cancer remains poor, with a 5-year survival rate of less than 20% (1). Cisplatin (CDDP) with infusional 5-fluorouracil (5-FU) and concurrent external beam radiotherapy has been adopted as the standard treatment for unresectable esophageal cancers. However, based on randomized studies, there is controversy regarding the potential benefit of the neoadjuvant treatment of resectable tumors (2-5). With a less than 30% pathologic complete response achieved with the current schedule (6,7), predictive molecular markers indicating response or non-response to neoadjuvant treatment would be very helpful in selecting patients for future treatment protocols.

The excision repair cross-complementing gene 1 (ERCC1) is an excision nuclease in the nucleotide excision repair (NER) process of DNA repair pathways. In vitro and in vivo studies have shown that NER-deficient cells are hypersensitive to CDDP (8-11). ERCC1 mRNA levels have been shown to correlate with NER capacity. ERCC1 may influence the repair of platinum-DNA damage in vitro and in vivo. Various studies have evaluated the association of ERCC1 expression with response to CDDP-based chemoradiotherapy (CRT) and survival in patients with esophageal cancer, with conflicting results (12-14). This discrepancy may partly be due to the different histological types of esophageal cancer (squamous cell carcinoma and adenocarcinoma). To date, no predictive marker of the response to CDDP-based CRT is available for esophageal squamous cell carcinoma (ESCC) patients in a clinical setting.

Oxaliplatin (OXA) is a new platinum analog containing a diamino cyclohexane platinum (DACH) carrier ligand. OXA forms platinum-DNA adducts at the same nucleotide level as CDDP, distorting DNA conformation and blocking replication and transcription. Studies culturing cancer cells have demonstrated that these DACH adducts induce cell death efficiently,
The present study comprised 16 patients with esophageal squamous cell carcinoma (ESCC) treated with 30-40 Gy of radiation, followed by esophageal resection. Cisplatin (cddP) was administered intravenously for 5 days concurrently with 5-fluorouracil (5-Fu) and pyrimethamine (Tegafur and uracil) dispensed orally for 5 days, plus 8 mg/day of biweekly gemcitabine (uFT). Patients received systemic 5-Fu and cddP chemotherapy in 4 cycles of 600 mg/m² with concurrent radiation according to the following regimen: patients received systemic 5-Fu and cddP chemotherapy and biweekly gemcitabine (uFT) with concurrent radiation. Cisplatin-based chemoradiotherapy regimen. Sixteen ESCC patients received systemic 5-Fu and CDDP chemotherapy with concurrent radiation according to the following regimen: 4 cycles of 600 mg/m² 5-FU over 24 h by continuous intravenous administration given every week, 400 mg/body weight UFT (Tegafur and Uracil) dispensed orally for 5 days, plus 8 mg/day CDDP administered intravenously for 5 days concurrently with 30-40 Gy of radiation, followed by esophageal resection.

The degree of histopathologic response was categorized as: grade 0, neither necrosis nor regressive changes; grade 1, >2/3 vital residual tumor cells (VRTCs); grade 2, <1/3 VRTCs; and grade 3, no VRTCs (19).

Clinical and histopathologic response to chemoradiotherapy. Tumor stage was evaluated based on the International Union Against Cancer tumor-node-metastasis (TNM) classification system (18). Clinical responses to CRT were evaluated by barium swallow, endoscopy, and computed tomography. In accordance with the Guidelines for clinical and pathologic studies on carcinoma of the esophagus (1999), clinical responses were graded as complete response (CR), partial response (PR), no change (NC) or progressive disease (PD) (19).

In cases of disease progression, the radiation dose was increased to a total of 60 Gy for definitive CRT. The time interval between neoadjuvant CRT and surgery was 2-3 weeks.

**Materials and methods**

**Patients and sample collection.** The present study comprised 16 patients (15 male and 1 female, median age 65 years, range 53-77) with ESCC diagnosed between 2001 and 2006. Selection criteria included the availability of cancer and normal biopsy specimens with complete clinical data and the quality of isolated RNA for real-time PCR.

Of the 16 patients, 11 (68.8%) underwent esophageal resection following chemoradiotherapy. The other 5 received definitive CRT as they refused to undergo surgery due to the risk involved in R0 resection. Endoscopic biopsy samples of the pre-treatment tumor and adjacent normal esophageal tissues were obtained from these patients. Normal esophageal mucosa was collected at a suitable distance from the primary tumor. Biopsy samples of post-treatment tumor tissues were taken from 13 patients 2 weeks after CRT. All biopsy specimens were snap frozen in liquid nitrogen and maintained at -80˚C until use. Prior to undergoing the pre-treatment endoscopic biopsies, all patients signed an informed consent form approving the experimental use of the tissues collected.

**Cisplatin-based chemoradiotherapy regimen.** Sixteen ESCC patients received systemic 5-FU and CDDP chemotherapy with concurrent radiation according to the following regimen: 4 cycles of 600 mg/m² 5-FU over 24 h by continuous intravenous administration given every week, 400 mg/body weight UFT (Tegafur and Uracil) dispensed orally for 5 days, plus 8 mg/day CDDP administered intravenously for 5 days concurrently with 30-40 Gy of radiation, followed by esophageal resection.

**RNA extraction and cDNA synthesis.** All samples were homogenized with a Mixer MM 300 homogenizer (Qiagen Inc., Chatsworth, CA, USA). Total RNA was isolated using an RNasy Mini Kit (Qiagen Inc.) according to the manufacturer’s instructions. cDNA was synthesized with random hexamer primer and Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions.

**Real-time quantitative RT-PCR.** Real-time quantitative RT-PCR analysis was performed using an ABI PRISM 7700 Sequence Detection System (Applied Biosystems Inc., Foster City, CA, USA). Primers and probes for β-actin, which was used as a reference gene, were designed using Primer3 software (Biology Workbench version 3.2, San Diego Supercomputer Center, University of California, San Diego, CA, USA). Primers and probes for ERCC1 were synthesized according to published sequences (12), and are shown in Table I. PCR was conducted in a final volume of 25 µl with Taqman Universal PCR Master Mix (Applied Biosystems) using 0.5 µl of cDNA, 900 nM of each primer and 200 nM of the probe for the respective genes. Cycling conditions were 50°C for 2 min and 95°C for 10 min, followed by 40 cycles at 95°C for 15 sec and 60°C for 1 min.

**Quantitation of ERCC1 mRNA expression.** Relative gene expression levels were determined by the standard curve method.
method. The standard curves for ERCC1 and β-actin mRNA were generated using 5-fold serially diluted solutions of cDNA from the esophageal cancer cell line TE1. All standard curves were linear in the analyzed range with an acceptable correlation coefficient ($R^2$). The amount of target gene expression was calculated from the standard curve, and quantitative normalization of cDNA in each sample was performed using β-actin gene expression as an internal control. Finally, ERCC1 mRNA levels were expressed as ratios to β-actin mRNA levels. Real-time PCR assays were conducted in duplicate for each sample, and the mean values were used for calculations of mRNA expression levels.

**Esophageal squamous cell carcinoma lines and cell culture.** The human ESCC lines TE1, TE2, KYSE70 and KYSE150 were grown in monolayer cultures in RPMI-1640 (Sigma Aldrich, St. Louis, MO, USA) supplemented with fetal bovine serum [FBS, 10% (v/v), Gibco BRL, Tokyo, Japan], glutamine (2 mM), penicillin (100,000 U/l), streptomycin (100 mg/l) and gentamicin (40 mg/l) at 37°C in a 5% CO₂ environment.

For routine passage, cultures were split 1:10 upon reaching 90% confluency, generally every 3 days. Cells at passages 5-9 were used for all experiments, performed with exponentially growing cells.

**Anticancer agents.** Cisplatin was obtained from Sigma Aldrich. Oxaliplatin was a kind gift from Yakult Co., Ltd. (Tokyo, Japan). Drugs were reconstructed in 0.9% saline for CDDP and in distilled water for OXA, and then dissolved in appropriate concentrations with distilled water and stored at -20°C until use.

**Growth inhibition assay.** Cytotoxicity was evaluated by the WST-8[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt] colorimetric assay. Cancer cells (5000 cells/well) were seeded into 96-well plates (Becton Dickinson Labware, NJ, USA) in 100 µl of culture medium for 24 h prior to drug exposure.

After 24 h of pre-incubation, cells were treated with various concentrations of CDDP or OXA for 24 h. Following drug exposure, the medium was discarded and replaced with 90 µl of fresh medium followed by the addition of 10 µl WST-8 reagent solution (Cell Counting Kit, Dojindo Laboratories, Japan) and incubated for 2 h at 37°C in an incubator.

Cell viability was determined using colorimetric comparison by reading optical density (OD) values from a microplate reader (SoftMax, Molecular Devices Corp., CA) at an absorption wavelength of 450 nm. Cytotoxicity was evaluated by the Cell Counting kit according to the manufacturer's instructions.

**Statistical analysis.** All statistical analyses were carried out using JMP version 5 (SAS Institute Inc., Cary, NC, USA). For the analysis of the cell line experiment, data were represented as the mean of at least 3 independent experiments. The difference in cell viability among the 4 cell lines at each drug concentration was estimated using the Kruskal-Wallis rank sum test.

For the analysis of patient samples, results were expressed as the median value (inter-quartile range). Differences in ERCC1 levels between pre-treatment cancer and adjacent normal biopsies were evaluated using the the Mann-Whitney U test. Associations between ERCC1 levels (continuous variables) and clinicopathological variables (categorical variables) were evaluated using the Mann-Whitney U test for two groups or the Kruskal-Wallis rank sum test for multiple groups. The paired t-test was used to compare ERCC1 levels during CRT. p-values <0.05 were considered statistically significant.

**Results**

**Clinicopathological variables and ERCC1 mRNA levels.** As shown in Table II, there was no statistically significant association between clinicopathological variables and ERCC1 levels. However, pre-treatment ERCC1 levels tended to be higher in older (>65 years of age) patients than in younger ones (p=0.09).

**Clinical and histopathologic response.** Clinical and histopathologic responses are shown in Tables III and IV, respectively. Of the patients, 11 (69%) were classified as partial response and 5 (31%) as no change. According to the histopathological response criteria, 3 (27%) of the 11 patients who underwent esophageal resection following CRT were categorized as grade 2, and 8 (73%) as grade 1. No significant correlation was observed between clinical and histopathologic response.

**Pre-treatment ERCC1 mRNA levels in cancer and normal tissue.** ERCC1 expression values (relative mRNA levels) were expressed as the ratio between ERCC1 (the gene of interest) and β-actin (the internal reference gene). This provided a normalization factor for the amount of RNA. The median pre-treatment ERCC1 mRNA level in endoscopic tumor biopsies was 0.74 (inter-quartile range 0.51-1.13), whereas in adjacent normal biopsies it was 0.60 (inter-quartile range 0.43-1.50). Pre-treatment ERCC1 was significantly overexpressed in ESCC tissues compared to its expression in adjacent normal tissues (p=0.0044) (Fig. 1).
Change in ERCC1 mRNA levels during cisplatin-based chemoradiotherapy. Of the 16 patients treated with CRT, 13 had both pre- and post-treatment tumor biopsy samples available for analysis.

ERCC1 mRNA levels were significantly lower in post-treatment tumor biopsies compared with their pre-treatment counterparts (p=0.0103) (Fig. 2). The ERCC1 level in post-treatment tissues was downregulated in 11 (85%) of the 13 ESCC patients treated with CDDP-based CRT compared with the levels found in their pre-treatment tissues.

Association of clinical and histopathologic response with ERCC1 mRNA levels. Patients with partial response (PR) to CDDP-based CRT had significantly lower ERCC1 mRNA
levels compared with those who did not respond to treatment (NC) (p=0.0107) (Fig. 3). However, no significant correlation was found between pre-treatment tumoral ERCC1 mRNA levels and histopathologic response (data not shown).

ERCC1 mRNA levels in esophageal cancer cell lines. To assess the relationship between ERCC1 and sensitivity to CDDP and OXA, ERCC1 mRNA levels were determined in 4 ESCC cell lines. Relative ERCC1 mRNA was 1.29 in TE1, 3.18 in TE2, 0.47 in KYSE70 and 0.47 in KYSE150. TE1 and TE2 had higher ERCC1 levels, and KYSE70 and KYSE150 had lower ERCC1 levels.

Association of ERCC1 with platinum drug sensitivity. The sensitivity of platinum drugs (CDDP and OXA) was compared in the 4 ESCC cell lines. Responses to platinum drugs showed anticancer activity in a dose-dependent manner (Fig. 4). Clinically relevant concentrations for CDDP and OXA were 1-5 µM and 0.25-3 µM, respectively, using the plasma concentrations specified by each drug company as a reference. KYSE70 and KYSE150, with lower ERCC1, demonstrated significantly greater sensitivity to platinum drugs at clinically relevant concentrations (1-10 µM) than TE1 and TE2 with higher ERCC1 (p<0.01, Fig. 5). A decreased ERCC1 level was associated with sensitivity to platinum drugs in esophageal cancer.

Discussion

In the present study, we demonstrated that patients who responded to CDDP-based CRT had significantly lower ERCC1 mRNA levels in their pre-treatment endoscopic tumor biopsy with clinical response to cisplatin-based chemoradiotherapy in ESCC patients. Box and whisker plots were used to summarize the distribution of mRNA levels in normal and cancer tissues. The horizontal line in each box represents the 50th (median) quartile, and the upper and lower lines of each box represent the 75th and 25th quartiles, respectively. The whiskers indicate the range of the measurements.

Association of pre-treatment ERCC1 levels in endoscopic tumor biopsy with clinical response to cisplatin-based chemoradiotherapy in ESCC patients.
The association between ERCC1 and clinical outcome remains controversial in esophageal cancer patients treated with CDDP-based CRT followed by surgery (12-14). We showed that ERCC1 was significantly associated with clinical, but not with histopathologic, response. Although histopathologic response as opposed to clinical response appeared to be closely associated with survival, it has a critical disadvantage in that it can only be evaluated after the primary tumor has been resected. In contrast, clinical response plays an important role when tumor resectability is evaluated in locally-advanced and potentially resectable esophageal cancer. Since ERCC1 may predict clinical response to CDDP-based CRT, patient stratification and CRT regimen selection might be possible prior to pre-operative CRT.

We also showed that ERCC1 was significantly overexpressed in cancer tissue compared to normal tissue. The role of tumoral ERCC1 remains unclear (13,20,21); however, it may be involved in the intrinsic DNA damage-repair ability of tumor cells, and would thus indicate the extent of accumulated intratumoral DNA damage. High tumoral ERCC1 leading to increased NER activity may be related to resistance to DNA-damaging anticancer drugs such as CDDP and OXA.

OXA is a third-generation platinum compound that has demonstrated antitumor activity against various types of malignancies, both pre-clinically (15) and clinically (16). Although OXA has not been fully evaluated in esophageal cancer, an OXA-containing regimen has demonstrated significant antitumor activity and a favorable toxicity profile in patients with metastatic esophageal cancer (16,17). Our results support the idea that OXA may be clinically active in ESCC patients, and that ERCC1 may predict the response to OXA of ESCC patients.

Notably, tumoral ERCC1 was significantly decreased to normal levels following CRT. Pre-operative CRT followed by surgery has been shown to provide a pathologic complete response in 20-40% of esophageal cancer patients (6,7). However, locoregional and distant recurrence have been observed even in patients with pathologic complete response. The recurrence rates of patients who did and did not undergo pre-operative CRT were similar (22). Second-line therapy is strongly recommended for these patients. However, there is no standard therapy for recurrence following CDDP-based CRT in ESCC patients. The decreased ERCC1 levels we observed after CRT indicate that platinum drugs as a second-line chemotherapy may still be appropriate for recurrent and metastatic esophageal cancer.

There are some limitations to this study, particularly in terms of the small number of clinical samples. Consequently, the results and their statistical significance should be interpreted with caution.

In conclusion, low ERCC1 expression was associated with CDDP and OXA sensitivity in ESCC cell lines. Pre-treatment tumoral ERCC1 appears to be a promising biomarker for predicting pre-operative clinical response in ESCC patients treated with CDDP-based CRT.
References


